Clinical Trial

Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure

Completed Phase 2/3
View on ClinicalTrials.gov →
Summary
Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-06.
Status change: Recruiting → Completed 2026-01-17
Trial Details
NCT Number NCT07064720
Lead Sponsor Cairo University
Conditions Dexmedetomidine
Enrollment 60 participants
Start Date 2024-07-12
Primary Completion 2025-12-22 (estimated)
Study Completion 2026-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-21